CG-34 CAR-T / CellenGene - LARVOL DELTA

CellenGene Inc. is acquiring Technology to Develop Ovarian Cancer 'CAR-T' Therapy...Patent acquisition in Australia [Google translation] (CellenGene Press Release) - "Cellengene...announced on the 7th that it had recently obtained an Australian patent...The patent covers the mini-antibody CG-3 scFv that binds to different parts of mesothelin and its use....Cellengene is a company that developed CG-34 scFv, a mini-antibody that specically recognizes mesothelin antigen related to solid tumors."

Patent • Oncology • Solid Tumor

Cellengene, ’CG-3 scFv’ Obtained US patent for mesothelin CAR-T treatment [Google translation] (HIT News) - "Cellengene...announced on the 11th that the second US patent has been registered...Following CG-34 scFv, the company plans to develop a CAR-T treatment equipped with CG-3 scFv and commercialize it for pancreatic cancer and ovarian cancer, which are cancer types with high unmet demand...In addition, the company predicted that CG-3 CAR-T, equipped with a new antibody, could also be used for carcinomas that have developed resistance to Cellengene's existing treatment, 'CG-34 CAR-T'....'This U.S. patent registration diversifies Cellengene's CAR-T treatment pipeline and is the foundation for technology transfer.'" "

Patent • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor